# PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

> **NCT04300296** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

## Interventions

- **DRUG:** secukinumab 300 mg Q4W
- **DRUG:** secukinumab 300 mg Q2W
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04300296
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-27
- **Primary completion:** 2021-11-16
- **Final completion:** 2022-05-03
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04300296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04300296, "PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04300296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*